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Myelopoiesis is a complex process driven by essential transcription factors, including C/EBPa, PU.1,
RUNX1, KLF4 and IRF8. Together, these factors are critical for the control of myeloid progenitor cell
expansion and lineage determination in the development of granulocytes and monocytes/macrophages.
MicroRNAs (miRNAs) are expressed in a cell type and lineage speciﬁc manner. There is increasing evi-
dence that miRNAs ﬁne-tune the expression of hematopoietic lineage-speciﬁc transcription factors and
drive the lineage decisions of hematopoietic progenitor cells. In this review, we discuss recently
discovered self-activating and feed-back mechanisms in which transcription factors and miRNAs interact
during myeloid cell development. Furthermore, we delineate how some of these mechanisms are
affected in acute myeloid leukemia (AML) and how disrupted transcription factor-miRNA interplays
contribute to leukemogenesis.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hematopoiesis is a complex of stepwise processes controlled by
transcription factors that are expressed in a cell type- and devel-
opmental stage-dependent fashion. Delicate regulation of expres-
sion of transcription factors, such as CCAAT/enhancer-binding
protein alpha (C/EBPa), spleen focus forming virus proviral inte-
gration oncogene SPI1 (PU.1), runt related transcription factor 1
(RUNX1), kruppel-like factor 4 (KLF4) and interferon regulatory
factor 8 (IRF8) is crucial for myelopoiesis [1e5]. It has become
increasingly clear that the expression of miRNAs is essential for
normal hematopoiesis. For instance, expression of Dicer, the critical
RNAseIII enzyme for miRNA biogenesis [6], in hematopoietic stem
cells (HSCs) is indispensable for hematopoietic cell differentiation
in mice [7]. Conditional deletion of Dicer in HSCs, causing a full
depletion of miRNAs, results in complete loss of HSCs due to in-
duction of apoptosis and thereby loss of all hematopoietic cell
lineages [7]. MiRNAs control gene expression by recruitment of the, Erasmus University Medical
therlands.
y, Erasmus University Medi-
Netherlands.
.J.M. Leenen), s.erkeland@
B.V. This is an open access article uRNA-induced Silencing Complex (RISC) to 30-UTRs of protein-
coding transcripts in a sequence-dependent fashion [6]. In addi-
tion, recent data show strong evidence for miRNA activities in the
nucleus e.g. mediating epigenetic regulation and targeting long
non-coding RNAs [8,9]. Like transcription factors, the expression of
miRNAs in myeloid cells is highly cell type and developmental
stage-dependent. In this review, we will focus on the interplay
between the major myeloid transcription factors C/EBPa, PU.1,
RUNX1, KLF4 and IRF8 and miRNAs in the course of myeloid cell
development (Fig. 1). These interactions include essential regula-
tion of these transcription factors by miRNAs as well as the in-
duction of critical miRNAs by these myeloid transcription factors.
2. The interplay of C/EBPa with miRNAs in normal and
malignant myelopoiesis
The transcription factor C/EBPa is a master regulator of myeloid
differentiation [10]. C/EBPA is a single exon gene and encodes an
mRNA with two translation initiation sites, resulting in either a 42
kD (p42) or a 30 kD (p30) protein. C/EBPa-p42, but not C/EBPa-p30,
contains two N-terminal transactivation domains involved in the
repression of E2F transcription factors. Down-regulation of E2F
activity is an essential requirement for normal granulopoiesis [11].
In agreement, murine conditional C/ebpa null hematopoietic pro-
genitor cells are unable to develop into mature granulocytes and
are blocked in their differentiation at the common myeloidnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic overview of myeloid cell development. The hematopoietic stem cells (HSCs) and the early myeloid progenitor cells (multi-potent progenitor (MPP), common
lymphoid progenitor (CLP), common myeloid progenitor (CMP)) are indicated in red, the granulocyte-macrophage progenitor (GMP) and the macrophage progenitor are indicated in
purple. DC populations are indicated in green (monocyte and dendritic cell progenitor (MDP), common dendritic cell progenitor (CDP), monocyte derived DC (MoDC), plasmacytoid
DC (pDC), conventional DC (cDC)). The macrophage/monocyte populations (monocytes (Mo), macrophages (Mf)) are indicated in blue and the granulocytes are indicated in orange
(granulocyte progenitor (GP), polymorphonuclear neutrophil (PMN)). Transcription factors and examples of miRNAs regulating the different stages of myeloid differentiation are
indicated by the blue and black text respectively below the cell types. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of
this article.)
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expression by hyper methylation of its promoter, post-translational
modiﬁcations or frame shift mutations at the 50-end and point
mutations at the 30-end of the gene encoding the basic region-
leucine zipper domain lead to aberrant C/EBPa proteins, disrupt
the normal activities of C/EBPa and are all associated with AML
[10,13]. The AML cases with C/EBPA gene mutations are character-
ized by a unique miRNA expression proﬁle [14], strongly suggesting
that C/EBPa controls the expression of a speciﬁc set of miRNAs.
MiRNAs are essential for HSC survival, as indicated above. In
striking contrast to the ﬁndings in HSCs, miRNA expression is not
essential for survival of C/ebpa-positive hematopoietic progenitor
cells, as CRE-mediated deletion of Dicer in C/EBPa positive cells in
mice results in normal frequencies of myeloid progenitor cells in
the bone marrow [15]. However, these mice have a high number of
dysplastic myeloid cells in BM and blood and lack monocytes and
macrophages [15]. Thus, Dicer expression is essential for normal
differentiation of C/EBPa positive hematopoietic stem and pro-
genitors (HSPCs) into granulocytes and monocytes/macrophages.
Therefore, it's not surprising that C/EBPa directly or indirectly
regulates the expression of miRNAs that are essential for myeloid
cell development. A set of at least 20 miRNAs is found to be highly
active in C/ebpa-positive HSPCs, including Let-7, miR-17 and miR-
223, which are critical for the repression of genes involved in
stem cell biology and erythropoiesis [15]. In agreement, AML cases
with inactivating mutations in C/EBPA are characterized by low
level expression of a set of at least 28 miRNAs compared to other
AML samples, including miR-9 and Let-7 [14].
Recent data show that the expression level of miR-223 is tightly
regulated during myelopoiesis, indicating that activity of miR-223
in hematopoietic cells is highly dynamic. C/EBPa is lowly
expressed in HSCs. E2F1, a known antagonist of C/EBPa at this stage,
is a direct transcriptional repressor of MIR223 in HSCs (Fig. 2A). C/
EBPa is upregulated in early myeloid progenitor cells and directlyenhance the expression of miR-223 [9]. C/EBPa competes at the
MIR223 promoter with the transcription factor nuclear factor (NF)I-
A, an inhibitor of miR-223 expression, and upregulates miR-223
expression (Fig. 2A) [16]. Also, after passing a certain threshold,
miR-223 mediates repression of E2F1 expression thereby
enhancing its own expression, indicating a self-amplifying mech-
anism. Interestingly, C/EBPa-upregulated miR-223 is not only
loaded into RISC, but is also associated with the polycomb group
proteins (PcGs)-RNA-interfering complex. PcG complexes localize
into the nucleus and silence target gene expression [9]. For
instance, the PcG-miR-223 complex targets the promoter of NFI-A
at a region that contains miR-223 complementary sequences and
causes transcriptional repression [9]. The regulation of NFI-A levels
in myeloid progenitor cells is crucial for myeloid lineage decision,
because NFI-A induction drives erythropoiesis, whereas its down-
regulation enables granulopoiesis [16,17]. Because miR-223
strongly inhibits the expression of NFI-A, this C/EBPa-stimulated
process results in an activating circuitry that drives retinoic acid-
induced granulocytic differentiation (Fig. 2B) [16].
There is strong evidence for differentmechanisms that ﬁne-tune
the levels and activities of miR-223 in hematopoietic precursor
cells. For instance, transcriptional variants of primary miR-223 are
differentially expressed during hematopoiesis [18]. The longest
primary miR-223 transcript is expressed at the highest level in
CD34þ progenitors undergoing granulocytic differentiation, while
cells that undergomonocytic differentiation express low levels. The
expression of this variant is high in erythroid progenitors but de-
clines strongly during erythroid differentiation. In addition to the
long miR-223 variant, a shorter variant of primary miR-223 is
induced only during granulopoiesis, but not upon monocytic or
erythroid differentiation. Both primary miR-223 transcripts are
processed and contribute to the enhancement of mature miR-223
levels in granulocytic progenitor cells. These transcripts originate
from two different transcriptional start sites and are controlled by
Fig. 2. The interplay between C/EBPa and miRNAs. Arrows indicate stimulatory activity, while inhibitory activities are indicated by block-signs (–j). Notably, the signs are used as
such that they represent the functional link between the indicated factor before the sign and the next step. This implies that stimulation and inhibition are indicated per step and
not as the result of the whole represented cascade. A) E2F1 and NFI-A control the inhibition of granulopoiesis in stem cells. E2F1 and NFI-A inhibit transcription of miR-223. E2F1 is
highly expressed and activates miR-182, which is an inhibitor of C/EBPa. B) C/EBPa-induced self-activating loop during granulopoiesis. C/EBPa induction in myeloid progenitors
causes down-regulation of miR-182 and upregulation of miR-34 and miR-223. These three events represses the indicated inhibitors of C/EBPa such as E2F1, NFI-A and miR-182,
resulting in a further upregulation of C/EBPa. Furthermore, miR-223 represses MEF2C and LMO2, thereby inhibiting erythropoiesis and stimulating granulopoiesis.
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tion, PU.1 and C/EBPB are recruited to the distal MIR223 regulatory
region. The enrichment of these transcription factors in early
monocyte development explains the initial expression of miR-223
in monocytic cells. However, PU.1 and C/EBPB are released from
the promoter at late stages of monocytic differentiation, resulting
in a decreased expression of miR-223 in mature macrophages.
During erythroid differentiation, erythroid transcription factors
including gata-binding protein 1 (GATA-1), transcription factor 3
(TCF3, E2A), lim domain only 2 (LMO2) and T-cell acute lympho-
cytic leukemia 1 (TAL1), interact with the proximal transcriptional
start site of the MIR223 promoter and silence primary miR-223
transcription, thereby maintaining a low miR-223 expression.
Forced miR-223 expression suppresses erythroid differentiation of
K562 cells [18]. Vice versa, downregulation of miR-223 expression
in human CD34 þ cord blood cells results in the induction of LMO2,
which is a conﬁrmed target of miR-223, and expansion anddifferentiation of erythroid progenitor cells (Fig. 2B) [20]. Together,
these results strongly suggest that high miR-223 expression is
critical for normal granulopoiesis. Surprisingly, Mir223 KO mice
show enhanced progenitor cell proliferation, granulocyte differ-
entiation and activation [19]. This phenotype may at least in part be
explained by overexpression of the transcription factor mads box
transcription enhancer factor 2, polypeptide C (MEF2C) and E2F1,
which are direct targets of miR-223 [19,20].
The expression of C/EBPa itself is directly controlled by miR-
182-5p in HSCs via interaction with the 30-UTR of C/EBPA mRNA
(Fig. 2A) [21]. E2F1 is a strong activator ofMIR182 and overrules the
inhibitory effects of C/EBPa on well-conserved interaction sites
within the MIR182 promoter [21]. When C/EBPa is induced, an
auto-regulatory loop involving miR-182 is activated that results in
further C/EBPa induction, which is critical for granulopoiesis as
described above (Fig. 2B). C/EBPa-mediated upregulation of miR-34
expression strongly represses E2F3 expression, which is an
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competing C/EBPa binding at the MIR182 promoter, resulting in
transcriptional silencing of MIR182 [21]. In this way, enhanced C/
EBPa expression inhibits its negative regulators E2F1 and miR-182
via transcriptional activation of MIR223 and MIR34. Thus, these
miRNA-mediated mechanisms may largely explain the stable
myeloid cell determination of progenitor cells that is initiated by C/
EBPa.
More complexity to the network involving C/EBPa regulation of
granulopoiesis is added by the notion that other miRNAs than miR-
182 also control C/EBPa expression. An important role is ascribed to
miR-124, which targets C/EBPA transcripts [23]. The 30-UTR of C/
EBPA is 1.4 kb in length and contains two well-conserved 7mer-m8
sites for miR-124-3p. There are three copies of the MIR124a gene
and one copy of theMIR124b gene in the human genome. The genes
encodingMIR124a-1 andMIR124a-3, but notMIR124a-2, are located
within CpG islands. These CpG islands are aberrantly epigenetically
silenced in leukemia cells, strongly suggesting that MIR124 inacti-
vation is an acquired event in leukemogenesis [23,24]. Down-
regulation of miR-124a occurs most-frequently in AML cases with
t(15:17) by an unknown mechanism [24]. In addition, in cell lines
and isolated AML cells, MIR124 is silenced by ecotropic viral inte-
gration site 1 (EVI1) [25]. Treatment of leukemia cells with DNA-
demethylating agent 5-aza-20deoxycytidine (DAC) and histone
deacetylase inhibitor trichostatin A (TSA) causes strong down-
regulation of C/EBPa expression as a result of MIR124a reactivation
[23]. As suggested by the investigators, the epigenetic status of
MIR124a in AML cells may be an important predictor for the efﬁ-
ciency of epigenetic therapy [23]. Interestingly, overexpression of
miR-124 indirectly inhibits the expression of PU.1 b y the down-
regulation of C/EBPa, thereby affecting monocyte/macrophage
development and activation [26]. The functions of miR-124 as a
negative regulator of C/EBPa-induced myelopoiesis still needs
in vivo validation.
Loss of C/EBPa collaborates with oncogenic miRNAs in AML. For
instance, enhanced expression of miR-125b accelerates leukemo-
genesis in mice that carry a C-terminal mutant of C/ebpa (C/ebpa-
Cm) [27]. Furthermore, we have recently shown that forced
expression of miR-199-3p, a DNA-damage-induced miRNA that is
frequently upregulated in AML, in C/ebpa null progenitors causes
AML in mice [28]. Notably, overexpression of miR-106, a miRNA
that induces progenitor cell expansion but no oncogenic trans-
formation in this model, did not result in AML [28]. Collaboration of
C/EBPa loss and enhanced miR-155 levels in leukemogenesis has
been strongly suggested in subsets of AML characterized by acti-
vating mutations in FMS-related tyrosine kinase 3 (FLT3) [29]. The
most common mutations are in-frame internal tandem duplica-
tions (ITDs) in the juxtamembrane domain of the receptor FLT3 and
these occur in 30% of AML cases. FLT3-ITD receptors cause upre-
gulation of miR-155 b y constitutive activation of nuclear factor
(NF)-kB (p65), and signal transducer and activator of transcription 5
(STAT5). In addition FLT3-ITD causes reduced expression and ac-
tivity of C/EBPa by constitutive activation of the extracellular
signal-regulated kinase (ERK) 1/2 pathway and cyclin-dependent
kinase-1 (CDK1)-mediated phosphorylation of C/EBPa serine 21
[30,31]. We have recently shown that enhanced miR-155 expres-
sion in C/ebpa null myeloid progenitor cells causes AML indepen-
dently of additional signaling aberrations associated with FLT3-ITD
in mice [29].
Gene expression analysis showed that the transcription factor
PU.1, which is a well-studied target of miR-155, was downregulated
in FLT3-AML [29]. The main evidence for miR-155-mediated regu-
lation of PU.1 levels came from a study published by Lu et al. in
which the interaction of miR-155 and Pu.1 was well-studied in vivo
by mutating the miR-155 binding site in the 30-UTR of Pu.1 in mice(Pu.1155/155mice) [32]. Pu.1 homozygousmutantmicewere viable
and born at normal frequencies and without any clear aberrancies
in the numbers and proportions of lymphoid and myeloid cell
lineages. However, the Pu.1155/155 mutation resulted in a 2-fold
increased PU.1 protein level and caused a signiﬁcantly impaired
class switch recombination and a reduced plasma cell differentia-
tion of B-cells due to enhanced paired box gene 5 (PAX5) levels [32].
The effects of disrupted miR-155-mediated PU.1 regulation on the
functions of myeloid cell types still needs to be determined.
3. PU.1 miRNA interactions
The hematopoietic-speciﬁc transcription factor PU.1 binds to
GAGGAA sequences at regulatory elements of lineage-speciﬁc
genes [33]. PU.1 directly or indirectly regulates the expression of
several miRNAs involved in the control of macrophage develop-
ment including the upregulated miR-146a, miR-342, miR-338 and
miR-155 and downregulated miRNAs such as members of the
MIR17~92 cluster miR-19, miR-20 and miR-92. The interplay be-
tween PU.1 and these miRNAs have been recently reviewed by
Alemdehy et al. [34].
More recent work show that PU.1 controls the transcriptional
activation of miR-22 during monocyte/macrophage differentiation
[35]. Upregulated miR-22 promotes differentiation by targeting
EVI1 transcripts and increasing the c-JUN expression and c-JUN-
PU.1 interactions. MiR-22 is signiﬁcantly downregulated in AML
samples compared to normal CD34 þ bone marrow cells and pe-
ripheral mono nuclear cells (PMNCs) and may be an interesting
diagnostic marker. Forced expression of miR-22 in human leukemia
cell lines and in CD34þ cells of AML patients induced differentia-
tion, suggesting a potential value in AML therapy. Moreover, miR-
22 controls IRF8 and CSF1R (M-CSFR) expression, involved in dif-
ferentiation of dendritic cells (DC) (see below).
Downregulation of PU.1 collaborates with loss of P53 and causes
aggressive AML in mice [36]. The expression of the transcription
factor MYB is silenced by P53 in hematopoietic cells. The authors
discovered that MYB is an upstream regulator of Mir-155. Loss of
P53 in AML causes upregulation ofMYB andmiR-155 expression. As
a result, PU.1 expression is strongly decreased. This event signiﬁ-
cantly accelerates the pathogenesis of AML [36].
A study of Grassilli et al. showed that a network of ATRA-
induced PU.1 in collaboration with vav guanine exchange factor 1
(VAV1) upregulatesmiR-142 expression, which in turn supports the
differentiation of acute promyelocytic leukemia (APL) cells [37].
The positive correlation of PU.1 expression and miR-142 upregu-
lation was also found in a human induced pluripotent stem cell
(iPSC) model duringmyeloid progenitor cell differentiation induced
by SCF, Flt3-L, IL-6 TPO and IL-3 [38]. A more recent study by Sol-
omon et al., showed a different mechanism of PU.1-induced miR-
NAs in myeloid cell differentiation [39]. This study provides
evidence for a mechanism inwhich PU.1-upregulatedmiRNAs, such
as miR-342, miR-141 and miR-200c, downregulate genes involved
in lipid anabolism, including ATP citrate lyase (ACLY). In their
model, PU.1 controls the cell cycle by reducing the expression of
E2F1 through direct activation of miR-223 transcription. The
increased miR-223 level is sufﬁcient to downregulate E2f1, which is
a direct target of miR-223 (Fig. 2A, see above). These data suggest
that PU.1 controls a set of miRNAs involved in different aspects of
myeloid differentiation.
An intriguing ﬁnding concerning PU.1-controlled monocyte/
macrophage differentiation is recently described [40]. In this study
the authors show that PU.1 upregulates the expression of the long
non-coding monocytic RNA (Lnc-MC) during monocyte/macro-
phage differentiation. Lnc-MC binds and inhibits the activities of
miR-199a-2-5p, thereby preventing the repression of target
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ceptor type 1 B (ACVR1B), an important factor driving monocyte/
macrophage differentiation [41]. These data show that
PU.1eupregulated Lnc-MC stimulate differentiation by inhibiting
miR-199a-2-5p and thereby releasing ACVR1B expression.
4. The interplay between miRNAs and the transcription factor
RUNX1
The RUNX family of transcription factors consists of 3 members
(RUNX1, RUNX2 and RUNX3), which are highly conserved between
species and control the expression of genes that are cell lineage-
speciﬁc and important for normal mouse development [3]. Ge-
netic deletion of the RUNX1-encoding gene in mice causes lethality
at embryonic day E12,5, because of central nervous system (CNS)
defects [42]. RUNX1, also known as AML1, is a transcription factor
that is critical for normal hematopoiesis (Fig. 1). RUNX1 is the alpha
component of the core binding factor (CBF) and binds to the non-
DNA-binding partner CBFb, which is critical for regulation of
RUNX1 target genes. The role of RUNX1 in normal hematopoiesis
and leukemia has been reviewed recently in two publications
[3,43]. RUNX1 is frequently deregulated in AML due to chromo-
somal translocation, mostly t(8;21)(q22;q23), which generates a
fusion with eight twenty one (ETO, or RUNX1T1), in AML. RUNX1
has been shown to positively or negatively regulate the expression
of numerous miRNAs including miR-223 and the miR-222e221
cluster. Vice versa, several miRNAs target RUNX1 and regulate its
expression at different stages of hematopoiesis. Important insights
into RUNX1 activities in this miRNA network have been reviewed
by Rossetti et al. who describe the role of miRNA-mediated RUNX1
deregulation in human leukemia [44]. Here, we will discuss new
insights concerning the interplay of miRNAs with RUNX1 (Fig. 3).
Studies with knockout mice show that the deletion of the
Mir23a~Mir27a~Mir24-2 cluster directs the lineage commitment of
Multi-Potential Progenitor (MPPs) populations to differentiation
into Common Lymphoid Progenitor CLPs, while the total number of
MPPs is unchanged [45]. This ﬁnding has been conﬁrmed in
transplantation experiments with Mir23/ CD34þ lineage-
negative, Sca1-positive, c-Kit-positive cells (LSK) transplantation
into sub-lethally irradiated mice, where an increase in lymphoid
cell populations was observed 20 days post transplantation [45].
The change in differentiation capacity of stem cells is explained by
an increased lymphoid stem cell gene expression program and
enhanced expression of miR-23a targets including transcription
factors Runx1, special AT-rich sequence-binding protein1 (Satb1)
and Btb and cnc homologue 1 (Bach1) [45]. Together, these data
suggest that miR-23a and its target Runx1 play a pivotal role in the
myeloid-lymphoid fate decisions in hematopoiesis.
The miR-23a~miR-27a~miR-24-2 cluster of miRNAs controls
RUNX1 expression levels in human and murine hematopoietic cells
during megakaryopoiesis (Fig. 3A) [46]. RUNX1 transcripts may
have different isoforms containing 30-UTRs of different sizes
dependent on the usage of alternative polyadenylation signals [46].
However, miR-27a interaction sites are close to the translational
stop and therefore miR-27a is capable to potentially regulate all
RUNX1 isoforms [46]. Strikingly, RUNX1 itself induces the expres-
sion of miR-27a by direct binding to the promoter region of
MIR23a~MIR27a~MIR24-2 gene (Fig. 3A) [46]. The RUNX1 tran-
scripts containing the long 30-UTR sequence are less sensitive to
miR-27a-mediated repression compared to the short 30-UTR-con-
taining transcript, most-likely due to structural changes of the RNA
or by protection of RNA-binding proteins [46]. This allows for
simultaneous upregulation of RUNX1 and miR-23a, miR-27a, miR-
24-2 targeting other transcripts that need to be repressed during
megakaryopoiesis. In addition to this cluster, it has now becomeclear that RUNX1 controls the expression the MIR144~451 cluster
(Fig. 3B). This cluster is repressed by RUNX1 by its binding to the
promoter and to lesser extent the enhancer region of this gene [47].
This regulation by RUNX1 has been conﬁrmed in primary human
CD34þ cells [47]. Besides a role in immature progenitors, the
RUNX1-mediated repression of the MIR144/451 cluster occurs
during megakaryopoiesis [47]. The binding of RUNX1 to the
MIR144/451 promoter is accompanied by a decrease in histone
activation marks, H3K9ac and H3K4me3 and an increase in
repressive chromatin H3R2me2 mark. Silencing of MIR144/451 in
progenitor cells inhibits the miR-451-mediated erythropoiesis,
thereby allowing megakaryopoiesis (Fig. 3B).
The expression of RUNX1 needs to be tightly regulated during
myelopoiesis, which is at least in part controlled by RNA-binding
proteins [48]. When CD34þ progenitor cells differentiate into
monocytes and granulocytes upon in vitro stimulationwith colony-
stimulating factor (CSF) 1 or CSF3, several RNA-binding proteins are
differentially expressed. From these, KH-type splicing regulatory
protein (KSRP) is the most downregulated RNA-binding protein
during monocytopoiesis and most upregulated during gran-
ulopoiesis [48]. KSRP interacts with the miRNA biogenesis com-
ponents DGCR8 and DROSHA, thereby promoting the processing of
miR-129 (Fig. 3C) [48]. When KSRP is induced, miR-129 is pro-
cessed, targets RUNX1 and downregulates its translation. RUNX1
inhibits CSF3-receptor (CSF3R) expression. Therefore, miR-129-
mediated downregulation of RUNX1 causes an upregulation of
CSF3R and thereby promotes granulocytic differentiation [48]. This
is different inmonocytopoiesis, where there is no induction of KSRP
and therefore no miR-129-mediated inhibition of RUNX1. RUNX1
stimulates the expression of the CSF1R, thereby promoting mono-
cyte development [48]. Therefore, miR-129 is involved in mono-
cytic and granulocytic lineage determination by RUNX1 through
regulation by KSRP (Fig. 3C).
Studies in zebraﬁsh show a very different relation betweenmiR-
142 and runx1 in HSCs [49]. By using runx1 and cmyb levels as a
measure for HSC development, the authors show that a decrease in
miR-142 expression correlates with a decreased runx1 expression
[49]. This downregulation of runx1 is caused by interferon regu-
latory factor 7 (irf7), which is a direct target of miR-142 (Fig. 3D).
The mechanism of RUNX1 regulation via miR-142-controlled Irf7
was veriﬁed in mice [49]. Inhibiting miR-142 causes enhanced IRF7
levels, a decreased RUNX1 expression and a diminished colony
forming capacity of murine c-KitþCD34þ cells and splenocytes,
while normal miR-142 levels are associated with normal RUNX1
expression and normal HSC numbers [46]. The binding of C/EBPb,
PU.1 and RUNX1 to the Mir142 promoter has been shown in mac-
rophages (Fig. 3E) and an increase of miR-142 expression was
observed compared to ﬁbroblasts where only C/EBPb and RUNX1
bind to the promoter [50]. The expression of miR-142 was even
higher in DCs where RUNX1 partner CBFb, in addition to the other
transcription factors, was found to be enriched on the Mir142
promoter (Fig. 3F) [50]. The transcription factor PU.1 appears to be
critical for miR-142 expression and synergizes with RUNX1, C/EBPb,
and CBFb [50]. Together, these ﬁndings suggest that miR-142 con-
trols the expression of RUNX1 in HSCs. In macrophages and DC's
RUNX1 ﬁne-tunes the expression of miR-142.
In leukemia RUNX1-fusions are involved in silencing of miRNA
expression. Translocation t (8; 21) (q22; q22) involving RUNX1 and
the ETO gene generates the RUNX1-ETO fusion oncoprotein. The
RUNX1-ETO oncoprotein directly inhibits the expression of miR-9-
1 (Fig. 3G), which is in concordance with the lack of miR-9-1
expression in clinical t(8;21)(q22;q22) AML [51]. This inhibition is
mediated by ﬁve putative RUNX1 binding sites that are present in
the regulatory region located 2 kb upstream of the MIR9-1 gene
(Fig. 3G). Luciferase reporter assays show that the RUNX1 binding
Fig. 3. RUNX1-controlled miRNA activities in different aspects of hematopoiesis. A) RUNX1 mediates the activation of miR-27. When miR-27 expression passes a certain
threshold, this results in speciﬁc downregulation of short RUNX1 transcripts during megakyopoiesis. B) RUNX1 inhibits the expression of miR-451~miR-144, thereby driving the
switch between erythropoiesis towards megakaryopoiesis. C) The RNA-binding protein KSRP activate the processing of pre-miR-129. Enhanced miR-129 expression results in the
downregulation of RUNX1 and the switch of monocytopoiesis towards granulopoiesis. D) Upregulation of miR-142 causes a down-regulation of IRF7, thereby inducing RUNX1
expression, which is critical for deﬁnitive hematopoiesis. E) C/EBPb, PU.1, RUNX1-mediated upregulation of miR-142 is important for macrophage development. F) CBFb enhance the
C/EBPb, PU.1, RUNX1-mediated expression of miR-142 and drives dendritic cell development. G) RUNX1 and the oncogenic fusion RUNX1-ETO are potent inhibitors of miR-9
expression, which is in turn an inhibitor of RUNX1-ETO. Inhibition of miR-9 is an oncogenic event in AML.
C.J. Stavast et al. / Cancer Letters 427 (2018) 28e37 33site in the region most proximal to the transcriptional start site is
sufﬁcient to silence the expression of miR-9-1 b y recruiting
epigenetic modulators such as histone deacetylase 1 (HDAC1) and
DNA methyltransferase 1 (DNMT1), DNMT3b in t(8;21)(q22; q22)
positive cells [51]. Interestingly, miR-9-1 directly targets RUNX1,
ETO, RUNX1-ETO and other downstream targets that are overex-
pressed in t(8;21)(q22;q22) AML (Fig. 3G) [51]. It is clear that
RUNX1-fusions repress the expression of their inhibitor miR-9.
Therefore, miR-9 may be interesting as a potential drug in treat-
ment of t(8;21)(q22;q22) AML.
5. KLF4 and miRNA regulation in myeloid cells
KLF4 plays an important role in myeloid differentiation at
different stages: differentiation of monocytic cells from myeloid
precursors [52,53] and polarization and activation of maturemononuclear phagocytes into alternatively activated M2-like cells
[54,55]. Related to KLF4 function and miRNA regulation in early
precursor differentiation (Fig. 4A), most information stems from
studies in leukemic cells. Proﬁling of miRNAs that are differentially
expressed betweenM1 (AML with minimal differentiation) and M5
(acute monocytic leukemia) identiﬁed 12 miRNAs that delineated
these two AML types [56]. Among these, miR-130a and miR-135 b
were shown to target KLF4. These miRNAs are down-regulated
upon induction of differentiation in AML cell lines with vitamin D
and phorbol-12-myristate-13-actate (PMA), with a concomitant
up-regulation of KLF4 expression. Interestingly, miR-130a also
targets IRF8, encoding another transcription factor involved with
myelomonocytic differentiation (see below). Mutations of the
nucleolar protein NPM1 occur frequently in AML. Comparison of
nucleophosmin 1 (NPM1)-mutated with NPM1-wt AML showed
overexpression of miRNAs, including miR-10a in the former [57].
Fig. 4. MiRNAs involved with regulation of monocytic differentiation from precursors induced by KLF4 (A) and activation of mature monocyte-derived cells (B). The meaning of the
signs are described in the legend of Fig. 2. A) In myeloid leukemia, miRNA-mediated inhibition of KLF4 enhances proliferation and represses differentiation of myeloid precursor
cells. B) Activation of mature monocyte derived cells is inhibited by indicated miRNAs.
C.J. Stavast et al. / Cancer Letters 427 (2018) 28e3734MiR-10a targets KLF4, and inhibition of miR-10a causes increased
AML cell death. Similarly, miR-10b overexpression is also
commonly observed in NPM1-mutated AML, causing KLF4 down-
regulation and limiting myeloid differentiation [58].
Functional involvement of KLF4 with precursor cell differenti-
ation includes induction of miR-150 expression (Fig. 4A) [59]. This
stimulates myeloid differentiation and inhibits proliferation of AML
cells [59]. Accordingly, the MIR150 promoter contains KLF-family
transcription factor binding sites. However, additional genes
other than onlyMIR150 are necessary to explain the KLF4 effects on
myeloid differentiation as manipulating expression of miR-150 and
the KLF4-target cyclin-dependent kinase inhibitor 1a (CDKN1a,
p21) did not fully recapitulate the KLF4 effects. Besides inducing
expression of CDKN1a, KLF4 also stimulates CDKN2b (p15)
expression [2,60]. Up-regulation of these CDKNs upon KLF4 in-
duction is a likely mechanism for effective cell cycle inhibition.
In mature monocyte-related cells, KLF4 drives polarization and
activation into alternatively activated M2-like cells [55]. Interest-
ingly, Kapoor et al. [54] showed that KLF4 promotes M2 polariza-
tion of macrophages by inducing MCP-1einduced protein (MCPIP).
The transcriptional activator MCPIP, in turn, induces expression of
C/EBPb and peroxisome proliferator-activated receptor-g (PPARg),
which are both transcription factors important for M2 polarization
(recently reviewed in Ref. [61]). Fig. 4B shows the involvement of
miRNAs in the regulation of KLF4 activity in mature cells. MiR-212-
5p was found upregulated upon fungal infection in monocyte-
derived DC and shown to inhibit KLF4 expression [62]. The same
group showed before that KLF4 is important for IL-6 induction in
fungal responses, and accordingly fungus-stimulated DC express
signiﬁcantly lower levels of IL-6 than DC stimulated by, for instance,
lipopolysaccharide (LPS) [63].
Infection of macrophages with Mycobacterium tuberculosis
causes down-regulation of miR-26a, which targets KLF4 [64]. This
allows increased KLF4 expression and causes a shift of polarization
from M1-to M2-like phenotype, as indicated by increased arginase
1 (ARG1) and decreased nitric oxide synthase 2 A (iNOS) expres-
sion. This route of M2 polarization is further favored by simulta-
neously increased C/EBPb signaling, probably mediated by KLF4
activity, as indicated above. M. tuberculosis infection also hampers
major histocompatibility complex class II (MHCII) expression by
macrophages. Ghorpade et al. showed that KLF4 expression isinduced in these cells by a nitric oxide-dependent mechanism [65].
Comparable to the situation in precursors, KLF4 induces expression
of miR-150, which inhibits the MHCII transcriptional activator
CIITA.
Several additional studies show KLF4 regulation by miRNAs in
other mesenchymal cell types, such as vascular endothelial cells
and smoothmuscle cells [66e69]. Of these, miR-92a, miR-103, miR-
143 and miR-145, amongst others, have been reported to be
expressed also by myeloid cells, and therefore it is likely that these
miRNAs have similar impact on KLF4 in myeloid function as well.
Notably, miR-143 and miR-145 appear to be associated with M2
polarization [70], and thus possibly ameliorates KLF4 protein
expression and function as negative feedback, but this remains to
be shown.
6. IRF8 and miRNA regulation in myeloid cells
In addition to KLF4, IRF8 operates in myeloid differentiation at
multiple stages [1]. It stimulates differentiation of monocytes from
myeloid progenitors [53] and differentiation of subsets of dendritic
cells [71], while inhibiting development of osteoclasts from
myeloid precursors [72] and suppressing neutrophil production
[73]. Furthermore, in line with its induction by interferon-gamma
(IFN-g), IRF8 is important in shaping macrophage and DC inﬂam-
matory phenotype and function [74,75]. IRF8 may heterodimerize
with other IRF family members to bind interferon-stimulated
response elements. In addition, IRF8 interaction with PU.1 ap-
pears to be essential for the production of IFN-b bymonocytes [76].
At several levels, miRNA regulation of IRF8 has been demon-
strated (Fig. 5). As described above, proﬁling of M1 and M5 sub-
types of leukemia identiﬁed 12 differentially expressed miRNAs
[56]. Among these, miR-130a and miR-181 were found to target
IRF8. These miRNAs were down-regulated upon induction of dif-
ferentiation in AML cell lines with vitamin D and PMA, with a
concomitant up-regulation of IRF8 expression. Interestingly, miR-
130a also targets KLF4, another transcription factor involved with
myelomonocytic differentiation at this stage (see above).
Studying the effect of polymorphisms inmiRNA-binding sites on
leukemia risk, Dzikiewicz-Krawczyk et al. observed an increased
Chronic Myeloid Leukemia (CML) risk associated with the
IRF8rs_10514611 allelic variant [77]. The T allele of
Fig. 5. MiRNAs involved with regulation of IRF8 in differentiation of (A) BM precursor cells and (B) mature osteoclasts and microglia. The meaning of the signs are described in the
legend of Fig. 2. Dashed block signs means indirect repression. A) MiR-22 controls the expression of IRF8, which determines the differentiation of DCs. In myeloid leukemia, miR-
130a and miR-181 aberrantly represses IRF8 in BM precursor cells resulting in an enhanced proliferation and reduced differentiation. B) In monocytes, miR-1270-mediated IRF8
mediates osteoclast differentiation. In microglia, miR-155-mediated repression IRF8 represses innate immune gene expression.
C.J. Stavast et al. / Cancer Letters 427 (2018) 28e37 35IRF8rs_10514611C> T was predicted to increase binding of miR-
330-3p but luciferase experiments failed to conﬁrm the pre-
sumed functional interaction.
Watowich and colleagues identiﬁed miR-22 as an important
regulator of IRF8 protein expression, determining differentiation of
mouse DC precursors into different subsets [78]. Overexpression of
miR-22mediated an enhanced generation of conventional DC (cDC)
at the expense of IRF8-dependent plasmacytoid (pDC) develop-
ment, while miR-22 knock-down caused the opposite effect. Not
only does miR-22 inﬂuence differentiation of DC precursor cells
into different subsets, we observed it also is induced in the ﬁnal
maturation step of monocyte-derived DC, where it targets CSF1R
[79]. Down-regulation of this homeostatic growth factor receptor is
required for these DC to achieve a phenotype associated with
antigen-presenting capacity.
Comparing miRNA expression proﬁles in circulating monocytes
of women with or without osteoporosis, Jimenez-Ortega et al.
found miR-1270 over-expressed in these osteoclast precursor cells
in osteoporosis [80]. MiR-1270 down-regulates expression of IRF8,
which is known to inhibit osteoclastogenesis [72]. Therefore,
increased expression of miR-1270 probably contributes to
increased generation of osteoclasts. Furthermore, miR-155 was
shown to decrease IRF8 expression in a human viral infection
model of microglial cells [81]. Bioinformatic analysis predicts IRF8
as one of the potential targets for miR-155, but testing of the 30-UTR
of IRF8 in the luciferase reporter system formiRNA target validation
did not conﬁrm a direct interaction.7. Concluding remarks
The regulatory role of miRNAs has been widely studied in he-
matopoiesis in the past decade. It has become evident that the
interplay between lineage-speciﬁc transcription factors and miR-
NAs is critical for normal differentiation and function of myeloid
cells. In this review we presented multiple examples of how miR-
NAs control cell lineage determination. In these examples miRNAs
downregulate molecular programs that are active at different
cellular states or in different cell types, implying their regulatory
contribution at multiple developmental levels. Deregulations of
miRNA activities are frequently seen in different types of leukemia,
underscoring the importance of proper miRNA regulation for
normal hematopoietic cell behavior. Although the molecular net-
works presented in this review are just a tip of the iceberg of the
complex mechanisms of myeloid differentiation and function, it is
clear that myeloid lineage-speciﬁc transcription factors fully rely on
miRNA activities to drive normal myeloid cell development.The networks controlled by miRNAs at the different stages of
myeloid differentiation are still largely elusive and the identiﬁca-
tion of essential miRNA target genes is technically challenging.
Although conventional miRNA function relies on the reverse com-
plementary interaction of miRNAs in the seed region with 30-UTRs
of mRNAs, increasing data show that the non-seed region plays a
role in the non-canonical functions of miRNAs [82e84]. Several
experimental observations discussed in this review indicate that
maturemiRNAs are also localized and active in the nucleus andmay
change the epigenetic status of myeloid progenitor cells. In addi-
tion, the RNA binding proteins controlling canonical miRNA activ-
ities and non-canonical nuclear localization and epigenetic
functions are mostly unidentiﬁed. Furthermore, it is becoming
more evident that long-non-coding RNAs are important mediators
of miRNA activity and cell type-speciﬁc gene expression. These
observations add even a new level of complexity to the regulatory
functions of transcription factors and miRNAs during myeloid cell
development. Understanding the complicated networks involved
in myeloid differentiation may open new avenues for therapeutic
intervention for the treatment of AML.
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